SMARTSTREAM
6.10.2020 10:02:07 CEST | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM® ) solutions provider, today announces SmartStream Air version 2, the latest artificial intelligence (AI) technology to transform data quality and reconciliation processes that would usually be measured in weeks and months, to just seconds. In addition, with cloud-based technology accessed via a new user interface it manages large volumes of data, in any format, to achieve even higher match rates.
SmartStream Air version 2 has been launched to enable organisations with a unique solution to instantly compare all types of data sets, regardless of format and complexity. The latest version features inbuilt observational learning capabilities with a new AI technology called ‘Affinity’ – which automatically learns how records correlate to one another and can mimic and learn from actions made by a user. In just a few clicks, the AI establishes its own understanding of how records correlate and Affinity will assist the user to significantly reduce the time it takes for carrying out the matching of complex data sets. Ultra-fast matching results are delivered to the end-user with high-quality results.
This is the next-generation AI solution to be developed in the SmartStream Innovation Lab, and it delivers data quality and verification processes in an elastic cloud-based deployment model, using the latest technologies and digital friendly services. Customers are up and running straight-away and the solution can transform traditional data verification processes within seconds. Introducing Affinity as part of version two ensures any manually changed data matching activities get learnt and adopted for the algorithm’s future use.
SmartStream Air version 2 carries the PCI-DSS label, which is the most recognised data security standard, and has been certified at the highest level of security standards when hosting digital payments data. SmartStream’s solutions are also certified with SOC 1, SOC 2, SOC 3, attestation, and ISO 27001 and ISO 27002 standard. This ensures robust security controls across the whole organisation, including physical security, personnel security, fraud control mechanisms, IT & data security and data privacy.
Andreas Burner, Chief Innovations Officer, SmartStream, states: “We have 13 years of experience with cloud technologies and fully understand how these platforms need to behave. Also, this combined with our data scientists’ work and our powerful SmartStream Innovation Lab, we have the right level of experience to trustfully bring AI cloud technologies to the market, unlike any other vendor in the market today. With our new version of SmartStream Air and the encompassing AI technology, Affinity, both these capabilities know what needs to be done and the results are a lot faster than before. I’m very proud of our achievements, most notably with the user experience design, that enables non-IT staff to take multiple complex data sets and compare them within seconds. What's been really compelling is that you don't even need to understand the data, Affinity knows how to compare complex data sets and the results are achieved in seconds - it’s that simple”.
Victoria Harverson, Global Head of Business Development for SmartStream Air, states: “SmartStream Air is like nothing else, it transforms traditional operating models as it behaves like a consumer app and requires no training or configuration, and no IT projects are needed. We understand that when it comes to managing data and finding discrepancies quickly it’s of paramount importance that our customers have a solution for every scenario and don’t miss a thing. Controlling risks, delivering transformation projects and optimising data quality processes is going to be easier than ever with this introduction of our next generation AI application”.
About SmartStream
SmartStream is a recognised leader in financial transaction management solutions that enable firms to improve operational control, reduce costs, build new revenue streams, mitigate risk and comply accurately with the regulators.
By helping its customers through their transformative digital strategies, SmartStream provides a range of solutions for the transaction lifecycle with AI and machine learning technologies embedded - which can be deployed in the cloud or as managed services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom